These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3271333)

  • 21. Safe and successful clinical use of the defibrinogenating agent ancrod.
    Glas-Greenwalt P
    Blood; 1992 Sep; 80(6):1626-8. PubMed ID: 1520890
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful treatment by defibrination with ancrod in a patient with hyperacute renal allograft failure and a deficiency of plasma prostacyclin stimulating factor.
    Dosekun AK; First MR; Chandran PK; Kant KS; Glas-Greenwalt P; Weiss MA; Alexander JW; Pollak VE
    Clin Nephrol; 1982 Aug; 18(2):101-5. PubMed ID: 6754189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic lowering of fibrinogen levels].
    Ernst E
    MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202
    [No Abstract]   [Full Text] [Related]  

  • 24. [Defibrination in the therapy of leg ulcers in diabetic microangiopathy].
    Hoting E; Wassilew S
    Z Hautkr; 1983 Feb; 58(3):181-4. PubMed ID: 6845792
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapeutic defibrinogenation as conservative therapy of peripheral arterial occlusive disease. A critical analysis].
    Ernst E
    MMW Munch Med Wochenschr; 1983 Sep; 125(37):796-8. PubMed ID: 6415441
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic defibrinogenation in peripheral vascular disease.
    Ernst E
    Int Angiol; 1985; 4(3):373-7. PubMed ID: 3913715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity.
    Dempfle CE; Argiriou S; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
    Ann N Y Acad Sci; 2001; 936():210-4. PubMed ID: 11460476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of heparin-induced thrombocytopenia and thrombosis.
    Green RM
    Semin Vasc Surg; 1996 Dec; 9(4):292-5. PubMed ID: 8958605
    [No Abstract]   [Full Text] [Related]  

  • 29. Expression and purification of ancrod, an anticoagulant drug, in Pichia pastoris.
    Yu X; Li Z; Xia X; Fang H; Zhou C; Chen H
    Protein Expr Purif; 2007 Oct; 55(2):257-61. PubMed ID: 17707656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Need for treatment of elevated plasma fibrinogen levels in cerebrovascular disease.
    Clark WM; Coull BM; Beamer NB
    Heart Dis Stroke; 1993; 2(6):503-6. PubMed ID: 8137058
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
    Pizzo SV; Schwartz ML; Hill RL; McKee PA
    J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ancrod-formed fibrin stimulates prostacyclin production of human umbilical vein endothelial cells via de novo synthesis of cyclooxygenase.
    Chang MC; Wang CY; Huang TF
    Biochem Biophys Res Commun; 1994 Sep; 203(3):1920-6. PubMed ID: 7945345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies.
    Levy DE; Trammel J; Wasiewski WW;
    J Stroke Cerebrovasc Dis; 2009 Jan; 18(1):23-7. PubMed ID: 19110140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The interaction of ancrod with human platelets.
    Kelton JG; Smith JW; Moffatt D; Santos A; Horsewood P
    Platelets; 1999; 10(1):24-9. PubMed ID: 16801067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antiplatelet activity of ancrod on administration to rabbits.
    Chang MC; Huang TF
    J Lab Clin Med; 1995 Apr; 125(4):508-16. PubMed ID: 7706907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Incidence of peptic ulcer in an inpatient angiologic patient sample].
    Creutzig A; Horstkotte H; Fischer M; Kleine P; Brunner G; Alexander K
    Leber Magen Darm; 1984 Jul; 14(4):161-3. PubMed ID: 6482641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glomerulonephritis and anticoagulants: therapy with dipyridamole in lupoid glomerulonephritis].
    Barlattani M; Guglielmi G; Mammarella A
    Clin Ter; 1972 Nov; 63(3):251-7. PubMed ID: 4644529
    [No Abstract]   [Full Text] [Related]  

  • 38. Desmin 370, a low molecular weight dermatan sulfate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod.
    Barbanti M; Calanni F; Marchi E; Semeraro N; Colucci M
    Thromb Haemost; 1995 Feb; 73(2):287-90. PubMed ID: 7792745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adhesion prevention with ancrod released via a tissue-adherent hydrogel.
    Chowdhury SM; Hubbell JA
    J Surg Res; 1996 Feb; 61(1):58-64. PubMed ID: 8769943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.